📄 ATTOVIA THERAPEUTICS, INC.

Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. Its lead candidate, ATTO-1310, is in a Phase 1 trial for chronic pruritus and atopic dermatitis, with additional candidates ATTO-2306 and ATTO-1091 in IND-enabling studies targeting atopic dermatitis and inflammatory bowel disease, respectively. The company has no approved products and has never generated revenue. Key risk: Limited operating history with no approved products or revenue, making evaluation of business and viability difficult. Proceeds: Advance clinical development of ATTO-1310, Advance clinical development of ATTO-2306, Advance research pipeline including ATTO-1091, other R&D, working capital, and general corporate purposes

Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. Its lead candidate, ATTO-1310, is in a Phase 1 trial for chronic pruritus and atopic dermatitis, with additional candidates ATTO-2306 and ATTO-1091 in IND-enabling studies targeting atopic dermatitis and inflammatory bowel disease, respectively. The company has no approved products and has never generated revenue.